Literature DB >> 26208580

Reoperation for Complications after Lumpectomy and Mastectomy for Breast Cancer from the 2012 National Surgical Quality Improvement Program (ACS-NSQIP).

Zahraa Al-Hilli1, Kristine M Thomsen2, Elizabeth B Habermann1,2, James W Jakub1, Judy C Boughey3.   

Abstract

BACKGROUND: Hospital readmissions and reoperations are quality indicators of patient care. In 2012, the National Surgical Quality Improvement Program (ACS-NSQIP) began reporting details regarding unplanned reoperations within 30 days of initial procedure. The main objective of this study was to identify reoperation rates as a result of complications and evaluate complications by type of breast surgery.
METHODS: Patients who underwent surgery for breast cancer were identified from the 2012 ACS-NSQIP Participant User File. Breast procedures were categorized as mastectomy or lumpectomy, each with or without immediate breast reconstruction (IBR). All reoperations and complication-related reoperations were categorized on the basis of procedure and diagnosis codes, and rates were compared by breast procedure by Chi square tests.
RESULTS: Of 18,500 patients, 781 (4 %) required an unplanned reoperation within 30 days (single reoperation in 747, 2+ reoperations in 34). Mean time to first reoperation was 13.4 days and varied by procedure. A majority (73 %) of ACS-NSQIP coded unplanned reoperations were due to complications. Rates of reoperation due to complication were highest in mastectomy with IBR (7 %). Most common complications requiring reoperation were bleeding, followed by infection and wound-related problems.
CONCLUSIONS: Unplanned reoperations after breast cancer surgery are more frequent after mastectomy with IBR than other breast operations. Bleeding is the most common complication requiring reoperation.

Entities:  

Mesh:

Year:  2015        PMID: 26208580     DOI: 10.1245/s10434-015-4741-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  Conceptual Considerations for Payment Bundling in Breast Reconstruction.

Authors:  Clifford C Sheckter; Shantanu N Razdan; Joseph J Disa; Babak J Mehrara; Evan Matros
Journal:  Plast Reconstr Surg       Date:  2018-02       Impact factor: 4.730

2.  Does neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer?

Authors:  Jeffrey Landercasper; Barbara Bennie; Mallory S Bray; Choua A Vang; Jared H Linebarger
Journal:  Gland Surg       Date:  2017-02

3.  Economic Impact of Reducing Reexcision Rates after Breast-Conserving Surgery in a Large, Integrated Health System.

Authors:  Jeffery M Chakedis; Annie Tang; Alison Savitz; Liisa L Lyon; Patricia E Palacios; Brooke Vuong; Maihgan A Kavanagh; Gillian E Kuehner; Sharon B Chang
Journal:  Ann Surg Oncol       Date:  2022-07-29       Impact factor: 4.339

4.  Long-term survival outcomes of repeat lumpectomy for ipsilateral breast tumor recurrence: a propensity score-matched analysis.

Authors:  Soo Yeon Baek; Jisun Kim; Il Yong Chung; Beom Seok Ko; Hee Jeong Kim; Jong Won Lee; Byung Ho Son; Sei-Hyun Ahn; Sae Byul Lee
Journal:  Breast Cancer Res Treat       Date:  2020-09-15       Impact factor: 4.872

5.  Indications for readmission following mastectomy for breast cancer: An assessment of patient and operative factors.

Authors:  Jennifer Yu; Margaret A Olsen; Julie A Margenthaler
Journal:  Breast J       Date:  2020-08-26       Impact factor: 2.431

6.  Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands.

Authors:  Coco J E F Walstra; Robert-Jan Schipper; Yvonne E van Riet; Peter-Paul G van der Toorn; Marjolein L Smidt; Maurice J C Vd Sangen; Adri C Voogd; Grard A P Nieuwenhuijzen
Journal:  Breast Cancer Res Treat       Date:  2021-03-13       Impact factor: 4.872

7.  Is there a role for homeopathy in breast cancer surgery? A first randomized clinical trial on treatment with Arnica montana to reduce post-operative seroma and bleeding in patients undergoing total mastectomy.

Authors:  Luca Sorrentino; Salvatore Piraneo; Eliana Riggio; Silvia Basilicò; Alessandra Sartani; Daniela Bossi; Fabio Corsi
Journal:  J Intercult Ethnopharmacol       Date:  2017-01-03

8.  Benchmarking the American Society of Breast Surgeon Member Performance for More Than a Million Quality Measure-Patient Encounters.

Authors:  Jeffrey Landercasper; Oluwadamilola M Fayanju; Lisa Bailey; Tiffany S Berry; Andrew J Borgert; Robert Buras; Steven L Chen; Amy C Degnim; Joshua Froman; Jennifer Gass; Caprice Greenberg; Starr Koslow Mautner; Helen Krontiras; Luis D Ramirez; Michelle Sowden; Barbara Wexelman; Lee Wilke; Roshni Rao
Journal:  Ann Surg Oncol       Date:  2017-11-22       Impact factor: 5.344

9.  Effect of Noninfectious Wound Complications after Mastectomy on Subsequent Surgical Procedures and Early Implant Loss.

Authors:  Katelin B Nickel; Ida K Fox; Julie A Margenthaler; Anna E Wallace; Victoria J Fraser; Margaret A Olsen
Journal:  J Am Coll Surg       Date:  2016-02-05       Impact factor: 6.113

10.  Postdischarge Nonsteroidal Anti-Inflammatory Drugs Are not Associated with Risk of Hematoma after Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia.

Authors:  Kate R Pawloski; Regina Matar; Varadan Sevilimedu; Audree B Tadros; Laurie J Kirstein; Hiram S Cody; Kimberly J Van Zee; Monica Morrow; Tracy-Ann Moo
Journal:  Ann Surg Oncol       Date:  2021-07-10       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.